Molecular Analysis for Therapy Choice (MATCH)

Study Overview

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Study Description

The purpose of this study is to evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

Additional Information:

Participants will not be paid for their participation.

Research Study Identifier: TX5399 Identifier: NCT1506163289 (EAY131/MATCH)
Principal Investigator: Kathy Miller, MD

Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.